How do I buy Dyne Therapeutics, Inc. Common Stock (DYN) stock?

Buying Dyne Therapeutics, Inc. Common Stock (DYN) stock is now easy and instant through the Gotrade app. Download the Gotrade app from the App Store or Google Play. Create an account and complete KYC. Make a deposit. Search for the code "DYN", then tap "Trade". Tap the "Buy" button. Enter the amount you want to buy. You have two options: Buy DYN by number of shares. Buy fractional shares in dollars, starting from $1. Swipe up to confirm your order, and you're done!

How do I tell if DYN is expensive or cheap?

There's no single perfect answer, but common approaches include: Compare valuation (e.g., P/E, P/S) against historical averages or competitors. Review revenue and earnings growth. Check margins and cash flow. Evaluate business outlook and the company's position within its industry. You can combine fundamental analysis with an investing strategy that matches your risk profile. All of the information above can be viewed directly in the Gotrade app.

Dyne Therapeutics, Inc. Common Stock (DYN) Stock

Q: What is the minimum investment for DYN on Gotrade?

On Gotrade , you don't have to buy a full lot. With fractional shares, you can start investing in Dyne Therapeutics, Inc. Common Stock from just $1. A small budget shouldn't stop you from building a US stock portfolio.

NASDAQ · DYN

Trade DYN

Key stats

Market cap: $2.92B
Price / Earnings ratio: -5.7x
EPS (TTM): -$3.32
Volume: Loading
52-week high: $27.31
52-week low: $14.00

Source: third-party data provider, as of October 25, 2026

Compare with DYN

Technical indicators

RSI 14: 41.48
MACD 12/26/9: -0.89
EMA 9 of MACD: -1.19
MACD histogram: 0.30
SMA 50: $19.48; Price below SMA 50
EMA 50: $18.27; Price below EMA 50
SMA 200: $19.33; Price below SMA 200
EMA 200: $19.29; Price below EMA 200

Calculated by Gotrade from daily closing prices, as of October 23, 2026. Technical data, not a recommendation.

Analyst ratings

Analyst consensus: Buy

Based on 7 analyst ratings

Strong Sell0

Sell1

Hold0

Buy6

Strong Buy0

Third-party analyst opinion, not a recommendation from Gotrade.

Financials

Performance

Revenue

Net income

Net margin %

2025

0000

Debt & Balance Sheet

Total assets

Total liabilities

2025

1B940M470M0

Revenue to Profit

2025

$0.0

Revenue

$0.0

Cost of revenue

$0.0

Gross profit

$0.0

Operating expenses

$-446.2M

Net income

Earnings

No data available

Source: third-party data provider

About Dyne Therapeutics, Inc. Common Stock

No description available.

SectorHealthcare

IndustryBiotechnology

Employees289

CEOMr. John G. Cox M.B.A.

IPO DateSep 17, 2020

HeadquartersWaltham, MA

Key Executives

Name	Title	Year Born
Mr. John G. Cox M.B.A.	CEO, President & Director	1963
Mr. Erick J. Lucera C.F.A., CPA	CFO, Principal Financial Officer & Principal Accounting Officer and Treasurer	1968
Dr. Oxana Beskrovnaya Ph.D.	Chief Innovation Officer	1961
Ms. Johanna Friedl-Naderer	Chief Commercial Officer	1968
Dr. Douglas Kerr M.B.A., M.D., Ph.D.	Chief Medical Officer	1967
Dr. Axel Wiest	Senior VP and Head of Portfolio Strategy & Operations	—
Dr. Rajesh Manchanda Ph.D.	Chief Technical Officer	1967
Mr. James P. Bilotta M.B.A.	Chief Digital & Information Officer	—
Mr. Alessandro Martuscelli	Chief Legal Officer	—
Ms. Lucia Celona	Chief Human Resource Officer	1966

Seasonality

Monthly price change (%)

	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec
2021										+3.9	-2.2	-6.1
2022	-39.5	+11.0	+11.3	-21.8	-43.5	+56.5	+45.7	-7.7	+20.2	-9.7	+8.9	-2.8
2023	+24.8	-11.8	-15.5	-6.2	+16.8	-12.0	+8.6	-3.7	-23.9	-11.2	+51.8	+18.8
2024	+63.9	+21.9	-2.5	-9.6	+23.4	+12.4	+20.9	+9.5	+12.5	-17.0	+6.5	-19.5
2025	-44.1	-1.9	-15.1	+27.7	-0.3	-25.0	+13.5	+34.2	-6.3	+80.6	-9.2	-5.1
2026	-3.3	-16.7	+12.3	-3.0	+11.2	+19.2	+15.6	+0.8	-35.8	-1.3

Stocks in the same sector

Vertex Pharmaceuticals

ABEO

Abeona Therapeutics Inc.

FAQ

Buying Dyne Therapeutics, Inc. Common Stock (DYN) stock is now easy and instant through the Gotrade app.

Download the Gotrade app from the App Store or Google Play.
Create an account and complete KYC.
Make a deposit.
Search for the code "DYN", then tap "Trade".
Tap the "Buy" button.
Enter the amount you want to buy. You have two options:
1. Buy DYN by number of shares.
2. Buy fractional shares in dollars, starting from $1.
Swipe up to confirm your order, and you're done!

On Gotrade, you don't have to buy a full lot. With fractional shares, you can start investing in Dyne Therapeutics, Inc. Common Stock from just $1. A small budget shouldn't stop you from building a US stock portfolio.

At the moment, Dyne Therapeutics, Inc. Common Stock (DYN) does not pay dividends because it focuses on reinvesting profits for company growth (a growth stock). However, you can still potentially earn profit from share price increases (capital gains). Track DYN's performance via the price chart in the Gotrade app.

Gotrade is the trading name of Gotrade Securities Inc., which is registered with and supervised by the Labuan Financial Services Authority (LFSA).

You can place orders 24/7. Transactions will be executed when the US market (NYSE/NASDAQ) is open, from 9:30 PM to 4:00 AM WIB, or 8:30 PM to 3:00 AM WIB during Daylight Saving Time. Gotrade also provides access to pre-market and after-hours trading, so you have more flexibility and aren't limited to regular working hours.

Market hours may change due to daylight saving time and holidays. In Gotrade, you can see the market status (open/closed) directly in the app.

There's no single perfect answer, but common approaches include:

Compare valuation (e.g., P/E, P/S) against historical averages or competitors.
Review revenue and earnings growth.
Check margins and cash flow.
Evaluate business outlook and the company's position within its industry.

You can combine fundamental analysis with an investing strategy that matches your risk profile. All of the information above can be viewed directly in the Gotrade app.

Trade Faster. Easier. Smarter.

#ReadyGoTrade

Welcome Reward up to $1,888

Create an account and trade US stocks on Gotrade

Download app

*Terms & conditions apply

Dyne Therapeutics, Inc. Common Stock (DYN) Stock

Key stats

Compare with DYN

Recent news

Wall Street Weighs Impact On DYN Stock Post Novartis’ Phase 3 Failure — RBC Says These Key Differences Could Lead To Better Outcomes

Wall Street Weighs Impact On DYN Stock Post Novartis’ Phase 3 Failure — RBC Says These Key Differences Could Lead To Better Outcomes

NVS Stock Clocks Worst Day In Over 20 Years After Second Trial Failure In A Week — DYN, SRPT Slip In Sympathy

NVS Stock Clocks Worst Day In Over 20 Years After Second Trial Failure In A Week — DYN, SRPT Slip In Sympathy

Dyne, Sarepta shares tumble as Novartis setback weighs on muscle disease drug developers

Dyne, Sarepta shares tumble as Novartis setback weighs on muscle disease drug developers

Why DYN Shares Are Down 10% After-Hours? Day After An FDA Win, Another Announcement Rocks Stock

Why DYN Shares Are Down 10% After-Hours? Day After An FDA Win, Another Announcement Rocks Stock

Technical indicators

Analyst ratings

Financials

Performance

Debt & Balance Sheet

Revenue to Profit

Earnings

Latest news

Wall Street Weighs Impact On DYN Stock Post Novartis’ Phase 3 Failure — RBC Says These Key Differences Could Lead To Better Outcomes

Wall Street Weighs Impact On DYN Stock Post Novartis’ Phase 3 Failure — RBC Says These Key Differences Could Lead To Better Outcomes

NVS Stock Clocks Worst Day In Over 20 Years After Second Trial Failure In A Week — DYN, SRPT Slip In Sympathy

NVS Stock Clocks Worst Day In Over 20 Years After Second Trial Failure In A Week — DYN, SRPT Slip In Sympathy

Dyne, Sarepta shares tumble as Novartis setback weighs on muscle disease drug developers

Dyne, Sarepta shares tumble as Novartis setback weighs on muscle disease drug developers

Why DYN Shares Are Down 10% After-Hours? Day After An FDA Win, Another Announcement Rocks Stock

Why DYN Shares Are Down 10% After-Hours? Day After An FDA Win, Another Announcement Rocks Stock

SRPT Stock Drops 4% As Citi Flags Potentially Stronger Rival In Duchenne Space

SRPT Stock Drops 4% As Citi Flags Potentially Stronger Rival In Duchenne Space

DYN Stock Rises 19.2% in 3 Months: What's Driving the Rally?

DYN Stock Rises 19.2% in 3 Months: What's Driving the Rally?

Dyne Therapeutics Trades Sideways Over An FDA Hurdle. Is It Time To Take Profits?

Dyne Therapeutics Trades Sideways Over An FDA Hurdle. Is It Time To Take Profits?

Dyne Therapeutics vs. Recursion Pharmaceuticals: Which Development Stage Pharma Stock Is a Better Buy in 2026?

Dyne Therapeutics vs. Recursion Pharmaceuticals: Which Development Stage Pharma Stock Is a Better Buy in 2026?

Dyne Therapeutics vs. Vertex Pharmaceuticals: Which Drug Innovator Stock Is a Better Buy in 2026?

Dyne Therapeutics vs. Vertex Pharmaceuticals: Which Drug Innovator Stock Is a Better Buy in 2026?

Dyne Therapeutics vs. Viking Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?

Dyne Therapeutics vs. Viking Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?

About Dyne Therapeutics, Inc. Common Stock

Key Executives

Fundamentals

Valuation

Profitability

Trading

Technical indicators

Analyst views

Seasonality

Compare stocks

Market cap

Price / Earnings ratio

Price / Sales ratio

Dividend yield

Average volume

Earnings per share

Stocks in the same sector

FAQ

Trade Faster. Easier. Smarter.

#ReadyGoTrade